Search Results - "Majem, M."

Use of archival versus newly collected tumor samples for assessing PD-L1 expression and overall survival: an updated analysis of KEYNOTE-010 trial by Herbst, R.S., Baas, P., Perez-Gracia, J.L., Felip, E., Kim, D.-W., Han, J.-Y., Molina, J.R., Kim, J.-H., Dubos Arvis, C., Ahn, M.-J., Majem, M., Fidler, M.J., Surmont, V., de Castro, G., Garrido, M., Shentu, Y., Emancipator, K., Samkari, A., Jensen, E.H., Lubiniecki, G.M., Garon, E.B.

“…In KEYNOTE-010, pembrolizumab versus docetaxel improved overall survival (OS) in patients with programmed death-1 protein (PD)-L1-positive advanced…”
Get full text

Acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in EGFR -mutant non-small cell lung cancer: A new era begins by Remon, J, Morán, T, Majem, M, Reguart, N, Dalmau, E, Márquez-Medina, D, Lianes, P

“…Abstract The discovery of mutated oncogenes has opened up a new era for the development of more effective treatments for non-small cell lung cancer patients…”
Get full text

Mechanisms of acquired resistance to first-line osimertinib: Preliminary data from the phase III FLAURA study by Ramalingam, S.S., Cheng, Y., Zhou, C., Ohe, Y., Imamura, F., Cho, B.C., Lin, M.-C., Majem, M., Shah, R., Rukazenkov, Y., Todd, A., Markovets, A., Barrett, J.C., Chmielecki, J., Gray, J.

Get full text

SEOM clinical guidelines for the treatment of non-small cell lung cancer (2018) by Majem, M., Juan, O., Insa, A., Reguart, N., Trigo, J. M., Carcereny, E., García-Campelo, R., García, Y., Guirado, M., Provencio, M.

“…Non-small cell lung cancer (NSCLC) accounts for up to 85% of all lung cancers. The last few years have seen the development of a new staging system, diagnostic…”
Get full text

Osimertinib treatment based on plasma T790M monitoring in patients with EGFR-mutant non-small-cell lung cancer (NSCLC): EORTC Lung Cancer Group 1613 APPLE phase II randomized clinical trial by Remon, J., Besse, B., Aix, S. Ponce, Callejo, A., Al-Rabi, K., Bernabe, R., Greillier, L., Majem, M., Reguart, N., Monnet, I., Cousin, S., Garrido, P., Robinet, G., Garcia Campelo, R., Madroszyk, A., Mazières, J., Curcio, H., Wasąg, B., Pretzenbacher, Y., Fournier, B., Dingemans, A.-M.C., Dziadziuszko, R.

“…The APPLE trial aimed to evaluate the feasibility of longitudinal plasma epidermal growth factor receptor (EGFR) T790M monitoring for the best sequencing…”
Get full text

Antibiotic-exposed patients with non-small-cell lung cancer preserve efficacy outcomes following first-line chemo-immunotherapy by Cortellini, A., Ricciuti, B., Facchinetti, F., Alessi, J.V.M., Venkatraman, D., Dall'Olio, F.G., Cravero, P., Vaz, V.R., Ottaviani, D., Majem, M., Piedra, A., Sullivan, I., Lee, K.A., Lamberti, G., Hussain, N., Clark, J., Bolina, A., Barba, A., Benitez, J.C., Gorría, T., Mezquita, L., Hoton, D., Aboubakar Nana, F., Besse, B., Awad, M.M., Pinato, D.J.

“…Prior antibiotic therapy (pATB) is known to impair efficacy of single-agent immune checkpoint inhibitors (ICIs), potentially through the induction of gut…”
Get full text

SEOM clinical guidelines on nutrition in cancer patients (2018) by de las Peñas, R., Majem, M., Perez-Altozano, J., Virizuela, J. A., Cancer, E., Diz, P., Donnay, O., Hurtado, A., Jimenez-Fonseca, P., Ocon, M. J.

“…Nutritional deficiency is a common medical problem that affects 15–40% of cancer patients. It negatively impacts their quality of life and can compromise…”
Get full text

An update on molecularly targeted therapies in second- and third-line treatment in non-small cell lung cancer: focus on EGFR inhibitors and anti-angiogenic agents by Majem, M., Pallarès, C.

“…Docetaxel, pemetrexed and epidermal growth factor receptor tyrosine kinase inhibitors (gefitinib and erlotinib) are recommended second-line therapy for…”
Get full text

Multidisciplinary consensus statement on the clinical management of patients with stage III non-small cell lung cancer by Majem, M., Hernández-Hernández, J., Hernando-Trancho, F., Rodríguez de Dios, N., Sotoca, A., Trujillo-Reyes, J. C., Vollmer, I., Delgado-Bolton, R., Provencio, M.

“…Stage III non-small cell lung cancer (NSCLC) is a very heterogeneous disease that encompasses patients with resected, potentially resectable and unresectable…”
Get full text

Efficacy of nintedanib and docetaxel in patients with advanced lung adenocarcinoma treated with first-line chemotherapy and second-line immunotherapy in the nintedanib NPU program by Corral, J., Majem, M., Rodríguez-Abreu, D., Carcereny, E., Cortes, Á. A., Llorente, M., López Picazo, J. M., García, Y., Domine, M., López Criado, M P.

“…Purpose Both nintedanib/docetaxel and anti‐PD‐1/PD‐L1 immunotherapies have demonstrated efficacy as second‐line treatment of patients with advanced lung…”
Get full text

SEOM clinical guideline for the management of cutaneous melanoma (2020) by Majem, M., Manzano, J. L., Marquez-Rodas, I., Mujika, K., Muñoz-Couselo, E., Pérez-Ruiz, E., de la Cruz-Merino, L., Espinosa, E., Gonzalez-Cao, M., Berrocal, A.

“…Melanoma affects about 6000 patients a year in Spain. A group of medical oncologists from Spanish Society of Medical Oncology (SEOM) and Spanish…”
Get full text

Clinical management of cutaneous adverse events in patients on targeted anticancer therapies and immunotherapies: a national consensus statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology by Grávalos, C., Sanmartín, O., Gúrpide, A., España, A., Majem, M., Suh Oh, H. J., Aragón, I., Segura, S., Beato, C., Botella, R.

“…Progress in the understanding of many tumors has enabled the development of new therapies, such as those targeted at specific molecules involved in cell growth…”
Get full text

Treatment strategy optimization for patients with non-small-cell lung cancer harboring EGFR mutation: a Delphi consensus by Isla, D., de Castro, J., García-Campelo, R., Majem, M., Vicente, D., Juan-Vidal, O.

“…Aim To stablish a consensus on the treatment strategy for advanced non–small-cell lung cancer (aNSCLC) with epidermal growth factor receptor mutation (EGFRm)…”
Get full text

Malignant pleural mesothelioma: Treatment patterns and outcomes from the Spanish Lung Cancer Group by Remon, J., Nadal, E., Dómine, M., Ruffinelli, J., García, Y., Pardo, J.C., López, R., Cilleruelo, A., García-Campelo, R., Martín, P., Juan, O., González-Larriba, J.L., Provencio, M., Olmedo, E., Ponce, S., Cumplido, D., Barenys, C., Majem, M., Massutti, B., Rodriguez-Abreu, D., Porta, R., Sala, M.A., Martinez-Kareaga, M., Lianes, P., Reguart, N.

“…•Epidemiological report of mesothelioma treatment patterns and outcomes in Spain.•Despite multimodal intervention, outcomes remain poor (1-year OS of 53.2…”
Get full text

SEOM clinical guideline for the management of immune-related adverse events in patients treated with immune checkpoint inhibitors (2019) by Majem, M., García-Martínez, E., Martinez, M., Muñoz-Couselo, E., Rodriguez-Abreu, D., Alvarez, R., Arance, A., Berrocal, A., de la Cruz-Merino, L., Lopez-Martin, J. A.

“…The use of immune checkpoint inhibitors has emerged as an effective treatment option for patients with several tumor types. By increasing the activity of the…”
Get full text

Beyond EGFR TKI in EGFR -mutant Non-Small Cell Lung Cancer patients: Main challenges still to be overcome by Remon, J, Morán, T, Reguart, N, Majem, M, Carcereny, E, Lianes, P

“…Abstract First line epidermal growth factor receptor tyrosine kinase inhibitor (EGFR TKI) is the standard treatment in advanced EGFR -mutant Non Small Cell…”
Get full text

miRNA-197 and miRNA-184 are associated with brain metastasis in EGFR-mutant lung cancers by Remon, J., Alvarez-Berdugo, D., Majem, M., Moran, T., Reguart, N., Lianes, P.

“…Introduction The prognostic value of EGFR mutation in lung cancer patients with brain metastases is uncertain and therapeutic efficacy with EGFR TKI is…”
Get full text

A phase II study of retifanlimab, a humanized anti-PD-1 monoclonal antibody, in patients with solid tumors (POD1UM-203) by Di Giacomo, A.M., Schenker, M., Medioni, J., Mandziuk, S., Majem, M., Gravis, G., Cornfeld, M., Ranganathan, S., Lou, S., Csoszi, T.

“…POD1UM-203, an open-label, multicenter, phase II study, evaluated retifanlimab, a humanized monoclonal antibody targeting programmed cell death protein-1…”
Get full text

The predictive value of BRCA1 and RAP80 mRNA expression in advanced non-small-cell lung cancer patients treated with platinum-based chemotherapy by Bonanno, L., Costa, C., Majem, M., Favaretto, A., Rugge, M., Rosell, R.

Get full text

Prevalence of EGFR mutations in newly diagnosed locally advanced or metastatic non-small cell lung cancer Spanish patients and its association with histological subtypes and clinical features: The Spanish REASON study by Esteban, E, Majem, M, Martinez Aguillo, M, Martinez Banaclocha, N, Dómine, M, Gómez Aldaravi, L, Juan, O, Cajal, R, Gonzalez Arenas, M.C, Provencio, M

“…Highlights • The sample was representative of the Spanish aNSCLC population (most Caucasian). • EGFR mutation rate was 11.6% (82.6% exon 19 dels and 17.4%…”
Get full text